Monographie - Heparin sodium

Zadnji put ažurirano :
03/05/2024

Heparin sodium

Kemijska struktura

Nekomercijalni

Zaštićeni nazivi su indikativni i sastav ekscipijensa može biti različit ovisno o državi i laboratorijima

Arapin	Čile
Ateroclar	Italija
Clarisco	Italija
Epsoclar	Italija
Hepaflex	Finska, Norveška
Hepamax	Čile, Ekvador, Kolumbija
Heparin	Austrija, Danska, Finska, Grčka, Jugoslavija, Južna Afrika, Kanada, Madžarska, Nizozemska, Norveška, Ruski, S A D, Švedska, Švicarska, Tajland, Turska, Velika Britanija
Heparine	Belgija, Francuska
Heparinised	Australija
Heparstad	Njemačka
Liquemin	Švicarska, Turska
Liquemine	Brazil
Monoparin	Saudijska Arabija
Normoparin	Italija
Nuparin	Ekvador
Pharepa	Italija
Riveparin	Argentina
Sobrius	Argentina, Ekvador
Thrombophob	Njemačka

Bibliografija : Heparin sodium

	Vrsta	Publikacija
3	Časopis	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
36	Časopis	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
59	Časopis	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
66	Časopis	Avelar MA, Walker SE. Stability and compatibility of reconstituted hydromorphone with potassium chloride or heparin. Can J Hosp Pharm 1996 ; 49: 140-145.
73	Časopis	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Časopis	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Časopis	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Časopis	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
92	Časopis	Lee CY, Mauro VF, Alexander KS. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 606-608.
93	Časopis	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Časopis	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
129	Časopis	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
132	Časopis	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
150	Časopis	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
156	Časopis	Barberi-Hayob M, Merlin JL, Vigneron M, Conroy T. Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions. Anticancer Drugs 1995 ; 6: 163-164.
163	Časopis	Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA. Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. J Clin Pharm Ther 1994 ; 19: 127-133.
169	Časopis	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
174	Časopis	Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO. Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride. Am J Hosp Pharm 1990 ; 47: 1567-1571.
182	Časopis	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Časopis	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
187	Časopis	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
198	Časopis	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
214	Časopis	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
215	Časopis	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
240	Časopis	Lam XM, Ward CA, de C du M?e CPR. Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy. Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
244	Časopis	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Časopis	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Časopis	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Časopis	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Časopis	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
257	Časopis	Hunt-Fugate AK, Hennessey CK, Kazarian CM. Stability of fluconazole in injectable solutions. Am J Hosp Pharm 1993 ; 50: 1186-1187.
266	Časopis	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
288	Časopis	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
289	Časopis	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
295	Časopis	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Časopis	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Časopis	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Časopis	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Časopis	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
314	Časopis	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
315	Časopis	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
317	Časopis	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	Časopis	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Časopis	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Časopis	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Časopis	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
341	Časopis	Baker DE, Yost GS, Craig VL, Campbell RK. Compatibility of heparin sodium and morphine sulfate. Am J Hosp Pharm 1985 ; 42: 1352-1355.
377	Časopis	Pereira-Rosario R, Utamura T, Perrin JH. Interaction of heparin sodium and dopamine hydrochloride in admixtures studied by microcalorimetry. Am J Hosp Pharm 1988 ; 45: 1350-1352.
384	Časopis	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	Časopis	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
396	Časopis	Chilvers MR, Lysne JM. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications. Am J Hosp Pharm 1989 ; 46: 2057-2058.
397	Časopis	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
398	Časopis	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	Časopis	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
406	Časopis	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
479	Časopis	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Časopis	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Časopis	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Časopis	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
617	Časopis	Solomon DA, Nasinnyk KK. Compatibility of haloperidol lactate and heparin sodium. Am J Hosp Pharm 1982 ; 39: 843-844.
660	Časopis	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
738	Časopis	Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584.
763	Časopis	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
791	Časopis	Hensrud DD, Buritt MF, Hall LG. Stability of heparin anticoagulant activity over time in parenteral nutrition solutions. JPEN 1996 ; 20: 219-220.
813	Časopis	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
860	Časopis	Nelson RW, Young R, Lamnin M. Visual incompatibility of dacarbazine and heparin. Am J Hosp Pharm 1987 ; 44: 2028.
874	Časopis	Stiles ML, Allen LV, Mc Laury HJ. Stability of two concentrations of heparin sodium prefilled in CADD-Micro pump syringes. Int J Pharm Compound 1997 ; 1: 433-434.
891	Časopis	Matsuura G. Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents. Hosp Pharm 1992 ; 27: 200, 202, 209.
895	Časopis	Yao JDC, Arkin CF, Karchmer AW. Vancomycin stability in heparin and total parenteral nutrition solutions: novel approach to therapy of central venous catheter-related infections. JPEN 1992 ; 16: 268-274.
905	Časopis	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Časopis	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Časopis	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
963	Časopis	Schaaf LJ, Tremel LC, Wulf BG, Vernon KK. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside. J Clin Pharm Ther 1990 ; 15: 371-376.
1022	Časopis	Hutchinson SMW. Heparin and aminoglycosides instability. Drug Intell Clin Pharm 1986 ; 20: 886.
1041	Časopis	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1057	Časopis	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1058	Časopis	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1067	Časopis	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1070	Časopis	Balthasar JP. Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium. Am J Health-Syst Pharm 1999 ; 56: 1891.
1072	Časopis	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1084	Časopis	Raupp P, von Kriek R, Schmidt E, Pfahl HG, G?nther O. Incompatibility between fat emulsion and calcium plus heparin in parenteral nutrition of premature babies. Lancet 1988 ; 1(8587): 700.
1085	Časopis	Irving HD, Burbridge BE. Incompatibility of contrast agents with intravascular medications. Radiology 1989 ; 173: 91-92.
1135	Časopis	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1183	Časopis	Tunbridge LJ, Lloyd JV, Penhall RK, Wise AL, Maloney T. Stability of diluted heparin sodium stored in plastic syringes. Am J Hosp Pharm 1981 ; 38: 1001-1004.
1228	Časopis	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1232	Časopis	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1234	Časopis	Parkinson R, Wilson JV, Ross M, Denyer SP. Stability of low-dosage heparin in pre-filled syringes. Br J Pharm Pract 1989 ; 11: 34-36.
1258	Časopis	Tyler LS, Rehder TL, Davis RB. Effect of gentamicin on heparin activity. Am J Hosp Pharm 1981 ; 38: 537-540.
1289	Časopis	Hecq JD, Evrard JM, Gillet P, Grosdent N. Etude de stabilité visuelle du chlorhydrate de chlorpromazine, du chlorure de potassium, de la furosémide et de l’héparine sodique en perfusion continue. Pharmakon 1998 ; 116: 145-148.
1291	Časopis	Wright A, Hecker J. Long term stability of heparin in dextrose-saline intravenous fluids. Int J Pharm Pract 1995 ; 3: 253-255.
1315	Časopis	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1352	Časopis	Hasegawa GR, Eder JF. Dobutamine-heparin mixture inadvisable. Am J Hosp Pharm 1984 ; 41: 2588-2589.
1391	Časopis	Vanstone GL. Is heparin always compatible with TPN and fat emulsion admixtures? Can J Hosp Pharm 1998 ; 51: 271-272.
1393	Časopis	Lyall D, Blythe J. Ciprofloxacin lactate infusion. Pharm J 1987 ; 238: 290.
1410	Časopis	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1414	Časopis	Mayer JLR, Pascale VJ, Clyne LP, Malkus H, Santos FS, van Hoff J. Stability of low-dose vancomycin hydrochloride in heparin sodium 100 UI / ml. J Pharm Technol 1999 ; 15: 13-17.
1415	Časopis	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1420	Časopis	Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132.
1423	Časopis	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1468	Časopis	Sautou V, Chopineau J, Gremeau I, Chevrier R, Bruneaux F. Compatibility with medical plastics and stability of continuously and simultaneously infused isosorbide dinitrate and heparin. Int J Pharm 1994 ; 107: 111-119.
1490	Časopis	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	Časopis	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1506	Časopis	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Časopis	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1512	Laboratorija	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1625	Časopis	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Časopis	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1699	Časopis	Plaas S, Heck C, Kubrich M. Mischbarkeit von serotonin-antagonisten mit dexamethason und heparin. Krankenhauspharmazie 2000 ; 21: 107-109.
1703	Časopis	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.
1712	Časopis	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Časopis	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Časopis	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Časopis	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1801	Časopis	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1802	Časopis	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	Časopis	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1822	Časopis	Trissel LA, Seanz C. Physical compatibility of antithymocyte globulin (rabbit) with heparin sodium and hydrocortisone sodium succinate. Am J Health-Syst Pharm 2003 ; 60: 1650-1652.
1868	Časopis	Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D. Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange. Nutr Clin Metab 2003 ; 17: 8-14.
1906	Časopis	McQuade MS, Van Nostrand V, Shariter J, Kanike JD, Forsyth RJ. Stability and compatibility of reconstituted ertapenem with commonly used iv infusion and coinfusion solutions. Am J Health-Syst Pharm 2004 ; 61: 38-45.
1925	Časopis	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1937	Časopis	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1953	Časopis	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1979	Časopis	Wu CC, Wang DP, Wong CY, Lin YF. Stability of cefazolin in heparinized and nonheparinized peritoneal dialysis solutions. Am J Health-Syst Pharm 2002 ; 59: 1537-1538.
1982	Časopis	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2037	Časopis	Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B. Stability of heparin and physical compatibility of heparin/antibiotic solutions ... J Antimicrob Chemother 2005 ; 56: 951-953.
2057	Časopis	Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 2003 ; 51: 849-855.
2087	Časopis	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Časopis	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2100	Časopis	Gervas S, Gosalbez F. Estabilidad fisica y quimica del sulfato magnesico combinado con heparina sodica en solucion salina al 0,9 por 100. Farm Hosp 1995 ; 19: 38-40.
2108	Časopis	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Časopis	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2212	Laboratorija	Reteplase (Rapilysin®) - Summary of Product Characteristics Actavis UK Ltd 2015
2221	Časopis	Cober M.P, Johnson C.E. Stability of 70% alcohol solutions in polypropylene syringes for use in ethanol-lock therapy. Am J Health-Syst Pharm 2007 ; 64, 23: 2480-2482.
2233	Časopis	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Časopis	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Časopis	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Časopis	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2271	Laboratorija	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
2279	Časopis	Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
2335	Časopis	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2346	Časopis	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
2375	Časopis	Strong DK, Ho W, Nairn JG. Visual compatibility of vancomycin and heparin in peritoneal dialysis solutions Am J Hosp Pharm 1989 ; 46: 1832 - 1833.
3012	Časopis	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3125	Časopis	Baker D S, Waldrop Bruce, Arnold John. Compatibility and Stability of Cefotaxine, Vancomycin, and Ciprofloxacin in Antibiotic Lock Solutions Containing Heparin. Int J Pharm Compound 2010 ; 14, 4: 346-349.
3134	Časopis	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3152	Časopis	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3176	Plakat	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3184	Laboratorija	Hyaluronidase (Hyalase®) - Summary of Product characteristics. CP Pharmaceuticals 2005
3210	Časopis	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3212	Časopis	Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.
3216	Časopis	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Časopis	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Časopis	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3267	Laboratorija	Lipomed Laboratories Dacarbazine Lipomed - Summary of Product Characteristics Lipomed 2011
3294	Časopis	Humbert-Delaloye V, Berger M, Voirol P, Pannatier A. In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs EJHP 2012 ; 19: 57-64.
3327	Časopis	LaPlante K.L, Woodmansee S, Mermel L.A. Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. Am J Health-Syst Pharm 2012 ; 69:1405-1409
3372	Časopis	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3408	Časopis	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3463	Časopis	Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R. Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad. Nursing 2011 ; 29 :62-6
3464	Časopis	Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau. Compatibilidad física de la amiodarona en perfusión continua Enferm Clin 2011 21:25-29.
3465	Časopis	E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ;21:96-103.
3466	Časopis	B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3520	Laboratorija	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3525	Laboratorija	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3529	Laboratorija	Ciprofloxacin – Summary of Product Characteristics Hospira 2013
3531	Laboratorija	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3540	Laboratorija	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3548	Laboratorija	Cefepime (Maxipime®) - Summary of Product caracteristics. Bristol Myers Squibb 2007
3549	Laboratorija	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3562	Laboratorija	Ofloxacin (Tarivid®) - Summary of Product Characteristics Sanofi 2014
3577	Laboratorija	Daunorubicine (Daunoxome®) - Résumé des caractéristiques du produit Galen Limited
3580	Laboratorija	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3588	Laboratorija	Vancomycine (Vancocin®) - Résumé des caractéristiques du produit Sandoz 2011
3604	Laboratorija	Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012
3605	Laboratorija	Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit Lipomed 2010
3616	Laboratorija	Altéplase (Actilyse®) - Résumé des caractéristiques du produit Boehringer Ingelheim 2012
3617	Laboratorija	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3632	Laboratorija	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3637	Laboratorija	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
3640	Laboratorija	Mitoxantrone - Summary of Product Characteristics Hospira 2013
3643	Laboratorija	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3645	Laboratorija	Doxorubicin - Summary of Product Characteristics Accord Healthcare 2014
3665	Časopis	Ortega R, Salmer?n-Garc?a A, Cabeza J, Capit?n-Vallvey L.F, Navas N. Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer’s injection and stored in polypropylene syringes at 4 and -20°C. Am J Health-Syst Pharm 2014 ; 71:956-959
3674	Laboratorija	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3687	Laboratorija	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3728	Časopis	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Časopis	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Časopis	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3781	Časopis	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. EJHP 2015 ;22:1 56-58
3823	Časopis	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Časopis	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Plakat	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Plakat	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Plakat	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3920	Laboratorija	Levofloxacine - Résumé Caractéristique du Produit Fresenius Kabi 2018
3923	Časopis	Luu Y, Thigpen J, Brown S.D. Stability of sildenafil in combination with heparin and dopamine. Am J Health-Syst Pharm 2017 ; 74, 1: e64-e71
3934	Laboratorija	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
3956	Časopis	Bastani B; Amin K; Herr A. Prolonged Stability of Stored Vancomycin, Gentamicin, and Heparin for Use in the Antibiotic-Lock Technique. ASAIO Journal 2005 ; 51,6:761-763.
3958	Časopis	Henrickson K.J; . Powell K.R; . Schwartz C.L. A Dilute Solution of Vancomycin and Heparin Retains Antibacterial and Anticoagulant Activities . J Infect Dis 1988 ; 157, 3: 600-601.
3964	Časopis	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	Časopis	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	Časopis	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4056	Časopis	Kandel S, Zaidi S, Wanandy T, Ming L, Castelino R, Sud K, Patel R. Stability of ceftazidime and heparine in four different types of peritoneal dialysis solutions. Perit Dial Int 2017
4108	Časopis	Cruz K, Chrchwell M, Mauro V, Boddu. Physical compatibility of levetiracetam injection with heparin, dobutamine, and dopamine. Am J Health-Syst Pharm 2018 ;75;8:510-512
4145	Časopis	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4166	Časopis	Bowie H.M, Haylor V. Stability of heparin in sodium chloride solution. J Clin Pharm Ther 1978 3:211-214
4180	Časopis	Mendes K, Harmanjeet H, Sedeeq M, Modi A, Wanandy T, Zaidi S, Ming L, Castelino R, Sud K, Peterson G, Patel R. Stability of meropenem and piperacillin/tazobactam with heparin in various peritoneal dialysis solutions. Perit Dial Int 2018 ;38,6:430-440
4254	Časopis	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	Časopis	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4332	Plakat	Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI) Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI). JFSPH 2019 2019
4389	Časopis	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	Časopis	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4433	Časopis	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Časopis	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4491	Časopis	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4507	Časopis	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4528	Časopis	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	Časopis	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4556	Časopis	Dobson, S.R, Mauro, V.F, Boddu, S.H.S, Churchwell, M.D. The Physical Compatibility of Clinically Used Concentrations of Diltiazem Hydrochloride With Heparin Sodium. J Pharm Technol 2020 ; 36, 4: 126-129.
4603	Časopis	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4612	Časopis	Villaba-Moreno AM, Gil-Navarro MV, Cotrina-Luque J, Pérez-Moreno MA, Chamorro-de Vega E. Estabilidad de la solución de gentamicina y heparina para sellado de catéter. OFIL 2014 24;2:86-90
4651	Časopis	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4654	Plakat	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4698	Časopis	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4724	Časopis	Maktabi B, Howard MS, Baki G, Churchwell MD Intravenous Physical Compatibility of Heparin Sodium and Furosemide. Int J Pharm Compound 2022 ;26,6:522-526
4732	Časopis	Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E. Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration. Am J Health-Syst Pharm 2023 80, 3;164–170
4742	Časopis	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4768	Časopis	Kondo M, Genpei M, Watanabe K, Yoshida M, Tagui N, Fukao S, Sugaya K, Takase H. Y-site injection physical compatibility of remdesivr with select intravenous drugs used in palliative care and for treating coronavirus disease 2019. Journal of Nippon Medical school 2023

Mentions Légales